Home Investor Relations

Investor Relations

The Investment Case

Why Gammaa
Why Now

Gammaa sits at the intersection of regulatory access, export infrastructure, pharmaceutical-grade production intent, and a differentiated Ceylon origin story. Public materials also show early international outreach and institutional backing, which helps move the story beyond concept and into execution.

First-Mover Advantage
Sri Lanka’s first licenced medical cannabis cultivation and export company.
Compliance-Led Build
EU-GMP-compliant indoor facility positioning from the outset.
Export Oriented
Mirigama BOI-zone location with global market intent.
Institutional Backing
Backed by 3 of Sri Lanka’s leading institutions

Projected Financial Summary

A Growth Model Boardroom-Grade Figures

$52.2M
USD
Total Revenue
5-Year
$23.2M
USD
Profit Before Tax

5-Year
$97M
NPV (DCF)
Net Present Value

5-Yr + Terminal
115%
IRR
Internal Rate

of Return
3.4yr
PAYBACK
On USD 5M

Investment
19×
ROI
Return on

Investment
Revenue & EBITDA Trajectory
FY 2027–FY 2032 · Projected figures in USD millions
Gammaa Extracts (Pvt) Ltd
Forecasted Financials for the period from 2026 to 2032
(All Figures in USD Mn)
Period FY 2027 FY 2028 FY 2029 FY 2030 FY 2031 FY 2032
Total Revenue 500,000 4,800,000 4,899,000 9,737,100 13,291,227 18,939,880
EBITDA
(483,686)
 2,220,324 2,203,406 5,301,339 7,544,097 10,967,659
EBITDA% -97% 46% 45% 54% 57% 58%
Net Proifit before Tax
(1,296,402)
 1,496,820 1,419,861 4,570,817 6,813,575 10,237,137
Net Present Value
$97M
Payback Period
3.4 years
IRR
115%
ROI
19
Model based on approved internal assumptions. Wholesale dried flower: USD 2.00/g · High quality extract: USD 10.00/g · Ayurvedic product: USD 18.00/unit · Corporate tax: 30%. Figures remain subject to final board and auditor review. This does not constitute financial advice.

Investor Opportunity

Compliance-Led Export Opportunity

The opportunity is constructed around a unique regulatory position one that took two years to secure and cannot be easily replicated combined with premium Ceylon origin, scalable production intent, export-ready infrastructure, and commercial market relationships already in development. Investors enter at a conservative USD 10M valuation against a USD 98M NPV.
Become an Investor
USD 10M Current Valuation → USD 97M NPV
Conservative entry valuation of USD 10M against a DCF-based NPV of USD 97M; a 9.7× valuation multiple embedded in the base case model. IRR of 115% and payback of 3.4 years on a USD 5M investment.
Option A
USD 3.0M
30% equity share
Annual earnings (projected)
~$942K/yr
Equity value after 5 years
USD 29M
Return multiple
~9.7×
Option B
USD 1.5M
15% equity share
Annual earnings (projected)
~$471K/yr
Equity value after 5 years
USD 14.5M
Return multiple
~9.7×

Market Opportunity

Built for Regulated Demand
Not Speculative Hype

Sri Lanka

Production Origin

BOI Mirigama

Equatorial climate, biodiversity-rich terroir, 30–50% cost advantage over EU/North America, Ayurvedic licensing authority, and unlimited production scope across all cannabis forms.
License RCC4034/24/PL Permanent
Global Market Scale

Medical cannabis is a regulated pharmaceutical product in an expanding set of markets. Gammaa targets the premium, compliance-first pharmaceutical supply chain not retail consumer channels.

$444B
Global Market Projection
30–50%
Cost advantage vs EU
AAA+
Pharmaceutical Grade

Begin the Conversation

Ready to Explore
The Investment Case?